



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Thursday, November 26, 2009

Epitomics, Inc.

[View the current Epitomics, Inc. Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/22569-Epitomics%2C+Inc..html)

(<http://www.bioportfolio.com/biocorporate/22569-Epitomics%2C+Inc..html>)

Contact Details:

863 Mitten Road Suite 103
Burlingame
California
94010-1303
United States of America

Tel: (650) 583-6688
Fax: (650) 583-6680
Email: info@epitomics.com

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics, Inc. (www.epitomics.com) is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.

Recently, Epitomics was issued two important industry-changing patents that go a long way towards solidifying the company's position in the growing monoclonal antibody marketplace. To summarize the patents:

- Epitomics was issued patent no. 7,429,487, which covers the next generation of cells for producing rabbit monoclonal antibodies and further establishes Epitomics' unique position as *the* rabbit monoclonal antibody company.

- Epitomics was issued patent no. 7,431,927 covering a broad grouping of anti-TNF (Tumor Necrosis Factor) antibodies. This potentially industry-changing antibody patent provides a sweeping grant of exclusivity that will broadly cover any antibody that contains the binding region of a particular rabbit TNF-neutralizing antibody, as well as a large number of variant antibodies that contain amino acid substitutions in the antibody's binding region.

These are just two recent accomplishments – the founders of Epitomics have hundreds of antibody-related inventions to their credit and the company is continually innovating. Below are press releases detailing the two recent patents.

Press Releases on Epitomics, Inc.:

[Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment](#)

26th October, 2009 Reportlinker

-- A focus on "engineered" antibodies Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing

[Reportlinker Adds Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists](#)

16th October, 2009 Reportlinker

-- additional comments with a hyperlink leading to the source of information. Index -- 2008 Sales of VEGF/R Antagonists -- VEGF-R Agonists -- Cardiovascular

[Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results](#)

19th May, 2009

Simcere Pharmaceutical Group

NANJING, China, May 19 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading manufacturer and supplier of branded generic and

[Epitomics Appoints Dr. Zhiqiang An as Chief Scientific Officer](#)

16th December, 2008 Epitomics, Inc.

BURLINGAME, Calif., Dec. 16 /PRNewswire/ -- Epitomics, Inc., the world's sole provider of humanized rabbit monoclonal antibodies for therapeutic use, today announced the appointment of Zhiqiang

BioNews Results for Epitomics, Inc.



- [PRIMECAP Management Top Holdings: Amgen Inc., Eli Lilly and Company, Novartis AG, FedEx Corp., Google Inc., Me](#)
Guru Focus: Nov 22 2009 3:56PM Matching: inc
- [Guru Stocks at 52-Week Low: Genzyme Corp, Apollo Group Inc, Cogent Inc, AMERICAN PUBLIC EDUCATION, INC, Whitne](#)
Guru Focus: Nov 22 2009 5:13PM Matching: inc
- [N.J. index reaches a yearly high](#)
Asbury Park Press: Nov 22 2009 12:49PM Matching: inc
- [Analyst Choice Brings New Analysis on Level 3 Communications Inc., Arris Group Inc., Virgin Media Inc., The South Financial Group Inc., Wynn Resorts Limited and AMAG Pharmaceuticals Inc.](#)
Individual.com: Nov 21 2009 6:41AM Matching: inc
- [Stocks That Stand Out For Nov. 20th, 2009 Are ARTS, RFMD, CLDS, ACTC](#)
Pharmacy Choice: Nov 21 2009 1:27PM Matching: inc
- [Rothman Research Follow-up Study of Charles Schwab Corp., SIRIUS XM Radio Inc., Aastrom](#)

[Biosciences Inc., Sonic Corp., Zhone Technologies Inc. and United Community Banks Inc.](#)

Individual.com: Nov 21 2009 10:22AM Matching: inc

- [Medical News: KineMed Receives An Investigator-Initiated Study Grant To Further Explore Mechanism\(s\) Of Action Associated With Welchol In Type 2 Diabetes Melli](#)

BioFind: Nov 21 2009 6:38AM Matching: inc

- [KineMed Receives An Investigator-Initiated Study Grant To Further Explore Mechanism\(s\) Of Action Associated Wi](#)

Medical News Today: Nov 21 2009 4:01AM Matching: inc

- [Benefit raises money for child with cancer](#)

Southwest Florida Herald Tribune: Nov 20 2009 1:22PM Matching: inc

- [Check Us Out!!! Sign Up Now For Our Free Newsletter!! BRGO, QSAP, XCEL, XMDC, MTVO, GETA](#)

Pharmacy Choice: Nov 20 2009 10:26PM Matching: inc

- [Zacks Sell List Highlights: Hughes Communications Inc., Astec Industries, Inc., Abraxis Bioscience, Inc. and R](#)

Reuters: Nov 20 2009 12:25AM Matching: inc

- [Stocks on the move: Consol, Dell, Leap, LogMeln, Merck, Novavax](#)

Inside Bay Area: Nov 20 2009 6:36PM Matching: inc

- [ImmunoGen announces second license agreement with Amgen](#)

TradingMarkets: Nov 20 2009 7:56PM Matching: inc

- [The Fortune Financial Global Market Perspective Review on Schnitzer Steel Industries Inc., ViroPharma Inc., T.](#)

TradingMarkets: Nov 20 2009 12:58PM Matching: inc

- [Global market for anti-depressants on a decline](#)

News-Medical.Net: Nov 20 2009 11:09AM Matching: inc

Epitomics, Inc. Patents:



- 7575896- [Cell fusion method](#)
- 7462697- [Methods for antibody engineering](#)
- 7431927- [TNF.alpha.-neutralizing antibodies](#)
- 7429487- [Fusion partner for production of monoclonal rabbit antibodies](#)
- 7402409- [Cell fusion method](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership

username and password

- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

